- Home
- QCRH vs CVAC Comparison
QCRH vs CVAC Comparison
Compare QCRH & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- CVAC
- Stock Information
- Founded
- QCRH 1993
- CVAC 2000
- Country
- QCRH United States
- CVAC Germany
- Employees
- QCRH N/A
- CVAC N/A
- Industry
- QCRH Major Banks
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- CVAC Health Care
- Exchange
- QCRH Nasdaq
- CVAC Nasdaq
- Market Cap
- QCRH 1.2B
- CVAC 643.8M
- IPO Year
- QCRH 1993
- CVAC 2020
- Fundamental
- Price
- QCRH $81.72
- CVAC $2.82
- Analyst Decision
- QCRH Buy
- CVAC Hold
- Analyst Count
- QCRH 3
- CVAC 3
- Target Price
- QCRH $76.00
- CVAC $10.00
- AVG Volume (30 Days)
- QCRH 66.6K
- CVAC 399.6K
- Earning Date
- QCRH 10-23-2024
- CVAC 11-12-2024
- Dividend Yield
- QCRH 0.29%
- CVAC N/A
- EPS Growth
- QCRH N/A
- CVAC N/A
- EPS
- QCRH 6.74
- CVAC N/A
- Revenue
- QCRH $336,452,000.00
- CVAC $70,565,734.00
- Revenue This Year
- QCRH N/A
- CVAC $105.61
- Revenue Next Year
- QCRH $9.39
- CVAC N/A
- P/E Ratio
- QCRH $12.11
- CVAC N/A
- Revenue Growth
- QCRH 2.22
- CVAC 75.11
- 52 Week Low
- QCRH $45.84
- CVAC $2.22
- 52 Week High
- QCRH $82.00
- CVAC $6.30
- Technical
- Relative Strength Index (RSI)
- QCRH 72.53
- CVAC 38.84
- Support Level
- QCRH $73.77
- CVAC $2.79
- Resistance Level
- QCRH $75.57
- CVAC $2.89
- Average True Range (ATR)
- QCRH 1.80
- CVAC 0.11
- MACD
- QCRH 0.82
- CVAC -0.01
- Stochastic Oscillator
- QCRH 97.46
- CVAC 19.44
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely QCBT, CRBT, CSB, and GB. It generates revenue in the form of interest.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.